NRIX Nurix Therapeutics Roche deal
NRIX Nurix Therapeutics Roche deal
Calling: exa_web_search
- queries=["Nurix Therapeutics Roche deal", "Nurix Therapeutics partnership with Roche details"], post_search_concerns="I need to confirm the details of the partnership/deal between Nurix Therapeutics (NRIX) and Roche. I don't have this information in my training data or immediate tools."
On June 8, 2026, Nurix Therapeutics (NRIX) announced a global collaboration agreement with Roche to develop and commercialize bexobrutideg (NX-5948), a potential best-in-class oral Bruton’s tyrosine kinase (BTK) degrader.
The strategic partnership covers development in malignant hematology, immunology, and neurology.
The collaboration is designed to leverage Nurix’s expertise in targeted protein degradation alongside Roche’s global clinical and commercial infrastructure. The agreement is expected to close in the third quarter of 2026, pending customary antitrust clearance.
give chart of both last 7 days stock price
Calling: load
- start_date="2026-06-01", metrics=["close"], tickers=["NRIX", "RHHBY"]
DataFrame 148
OK nrix_rhhby_price (6 rows)
Calling: show_chart
- series=["close"], dataframe_id=148, title="Stock Price: NRIX vs RHHBY (Last 7 Days)"
Blob 66
DataFrame 148
OK nrix_rhhby_price (6 rows)
Calling: show
- dataframe_id=148
Blob 67
DataFrame 148
OK nrix_rhhby_price (6 rows)
Calling: load
- tickers=["RHHBY"], start_date="2026-06-01", metrics=["close"]
Error: No Alpaca price bars returned
The chart below tracks the stock performance of Nurix Therapeutics (NRIX) over the last 7 days. Please note that data for Roche (RHHBY) is unavailable through this service.
(Prices shown for the last 7 days, reflecting the market response to the partnership announcement on June 8, 2026.)